Table 1.
Ongoing clinical trials for novel agents in prostate cancer.
| Drug | Registry number | Completion | Enroll | Phase | Status | Patient group |
|---|---|---|---|---|---|---|
| TAK-700 (orteronel) | NCT01707966 | Jul 2020 | 1,486 | III | Recruiting | ADT + TAK-700 vs. ADT + bicalutamide |
| VT-464 | NCT02012920 | Aug 2016 | 141 | I, II | Recruiting | Treatment-naïve vs. previous abiraterone & Enz |
| JNJ-56021927 (apamutamide) | NCT01171898 | Oct 2026 | 1,500 | III | Recruiting | JNJ-56021927 vs. bicalutamide |
| BAY1841788 (ODM-201) | NCT02200614 | Jun 2020 | 1,500 | III | Recruiting | BAY1841788 vs. placebo |
| MLN8237 (alisertib) | NCT01799278 | Feb 2017 | 60 | II | Not recruiting | Neuroendocrine prostate cancer |
| PROSTVAC | NCT02649855 | Jan 2020 | 38 | II | Recruiting | Simultaneous vs. sequential docetaxel + prostvac |
| Ipilimumab | NCT01688492 | Sep 2016 | 57 | I, II | Not recruiting | Ipilimumab + abiraterone |
| EPI-506 | NCT02606123 | Dec 2017 | 166 | I, II | Recruiting | EPI-506 |
| DCVAC | NCT02111577 | Jun 2018 | 1,170 | III | Recruiting | DCVAC + chemotherapy vs. placebo + chemotherapy |
| AZD5363 | NCT02525068 | Jun 2018 | 136 | II | Recruiting | AZD5363 + Enz |
| Alisertib | NCT01848067 | May 2018 | 43 | I, II | Recruiting | Alisertib + abiraterone |
| OGX-011 (custirsen sodium) | NCT01578655 | Dec 2016 | 630 | III | Not recruiting | Custirsen + cabazitaxel vs. cabazitaxel |
| 177Lu-J591 | NCT00859781 | Dec 2018 | 140 | II | Recruiting | 177Lu-J591 + Keto vs. 111ln-J591+Keto |
| Olaparib | NCT01682772 | Dec 2016 | 89 | II | Recruiting | Olaparib |
| AMG386 | NCT01553188 | Feb 2017 | 23 | II | Not recruiting | Abiraterone + AMG386 vs. abiraterone |
| Galeterone | NCT01709734 | Aug 2017 | 144 | II | Recruiting | Galeterone |
| KPT-330 (selinexor) | NCT02215161 | Jun 2018 | 54 | II | Recruiting | KPT-330 |
| MK-3475 (pembrolizamab) | NCT02312557 | Jan 2017 | 28 | II | Recruiting | Pembrolizamab + enzalutamide |
| GX301 | NCT02293707 | Nov 2018 | 120 | II | Recruiting | GX301 |
| Everolimus | NCT00976755 | Dec 2017 | 37 | II | Not recruiting | Everolimus |
| TKI258 (dovitinib) | NCT01741116 | Jun 2016 | 44 | II | Recruiting | TKI258 |
| Onapristone | NCT02049190 | Dec 2017 | 75 | I, II | Recruiting | Onapristone |
| ODM-204 | NCT02344017 | May 2017 | 75 | I, II | Recruiting | ODM-204 |
| Carfilzomib | NCT02047253 | Apr 2018 | 28 | II | Recruiting | Carfilzomib |
| Reolysin | NCT01619813 | Dec 2016 | 85 | II | Not recruiting | Docetaxel + reolysin vs. docetaxel |
| CYT107 | NCT01881867 | Jan 2017 | 80 | II | Recruiting | CYT107 vs. no therapy |
| Indoximod | NCT01560923 | Apr 2017 | 50 | II | Recruiting | Indoximod vs. placebo |
| SHR3680 | NCT02691975 | Jun 2020 | 140 | I, II | Recruiting | SHR3680 |
| LY3023414 | NCT02407054 | May 2018 | 144 | II | Recruiting | LY3023414 + Enz vs. placebo + Enz |
| LEE011 (ribociclib) | NCT02494921 | Dec 2018 | 47 | I, II | Recruiting | Docetaxel + ribociclib |
| BKM120 | NCT01385293 | Dec 2016 | 66 | II | Not recruiting | BKM120 |
| LY2157299 | NCT02452008 | Jul 2019 | 60 | II | Recruiting | LY2157299 + Enz vs. Enz |
ADT, androgen deprivation therapy; Enz, enzalutamide.